Literature DB >> 21331277

Weekly paclitaxel in ovarian cancer-the latest success story.

A Jain1, B Dubashi, K S Reddy, P Jain.   

Abstract

Entities:  

Keywords:  Weekly paclitaxel; adjuvant chemotherapy; intraperitoneal chemotherapy; ovarian cancer

Year:  2011        PMID： 21331277      PMCID： PMC3031352          DOI： 10.3747/co.v18i1.680

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  8 in total

1.  Chemotherapy: Current drugs still have potential in advanced ovarian cancer.

Authors:  Thomas Hogberg
Journal:  Nat Rev Clin Oncol       Date:  2010-04       Impact factor: 66.675

2.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors:  Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

3.  Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.

Authors:  Maurie Markman; John Blessing; Stephen C Rubin; Joseph Connor; Parviz Hanjani; Steven Waggoner
Journal:  Gynecol Oncol       Date:  2005-12-02       Impact factor: 5.482

Review 4.  Intraperitoneal chemotherapy for ovarian cancer: overview and perspective.

Authors:  Gautam Rao; Marta Crispens; Mace L Rothenberg
Journal:  J Clin Oncol       Date:  2007-07-10       Impact factor: 44.544

5.  Dose-dense chemotherapy in advanced ovarian cancer.

Authors:  Michael A Bookman
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

6.  A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.

Authors:  Peter G Rose; Mary Smrekar; Nancy Fusco
Journal:  Gynecol Oncol       Date:  2005-02       Impact factor: 5.482

7.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Authors:  Noriyuki Katsumata; Makoto Yasuda; Fumiaki Takahashi; Seiji Isonishi; Toshiko Jobo; Daisuke Aoki; Hiroshi Tsuda; Toru Sugiyama; Shoji Kodama; Eizo Kimura; Kazunori Ochiai; Kiichiro Noda
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

8.  Weekly paclitaxel in the adjuvant treatment of breast cancer.

Authors:  Joseph A Sparano; Molin Wang; Silvana Martino; Vicky Jones; Edith A Perez; Tom Saphner; Antonio C Wolff; George W Sledge; William C Wood; Nancy E Davidson
Journal:  N Engl J Med       Date:  2008-04-17       Impact factor: 91.245
  8 in total
  5 in total

1.  Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo.

Authors:  Wei Li; Mei-Lin Liu; Jia-Hui Cai; Yun-Xian Tang; Ling-Yun Zhai; Jun Zhang
Journal:  Oncol Lett       Date:  2012-04-23       Impact factor: 2.967

Review 2.  Anticancer Activity of Toxins from Bee and Snake Venom-An Overview on Ovarian Cancer.

Authors:  Marius Alexandru Moga; Oana Gabriela Dimienescu; Cristian Andrei Arvătescu; Petru Ifteni; Liana Pleş
Journal:  Molecules       Date:  2018-03-19       Impact factor: 4.411

Review 3.  Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity.

Authors:  Celina Amaya; Elizabeth R Smith; Xiang-Xi Xu
Journal:  J Cancer       Date:  2022-04-18       Impact factor: 4.478

Review 4.  Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy - non-mitotic mechanisms of paclitaxel.

Authors:  Elizabeth R Smith; Marilyn Huang; Matthew P Schlumbrecht; Sophia H L George; Xiang-Xi Xu
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

5.  Breaking malignant nuclei as a non-mitotic mechanism of taxol/paclitaxel.

Authors:  Elizabeth R Smith; Xiang-Xi Xu
Journal:  J Cancer Biol       Date:  2021
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.